{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:21:29Z","timestamp":1778718089348,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T00:00:00Z","timestamp":1670716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The economic and clinical burden of haemophilia A is high. Primary prophylaxis with factor VIII replacement therapy is the recognised standard of care, but the emergence of non\u2010factor therapies, such as emicizumab, is extending treatment options for people with haemophilia A.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>There are currently no direct comparisons of efficacy or cost between recombinant factor FVIII Fc\u2010fusion protein efmoroctocog alfa (a recombinant factor FVIII Fc\u2010fusion protein referred to herein as rFVIIIFc) and emicizumab; therefore, a cost\u2010effectiveness model was developed to compare prophylactic treatment with rFVIIIFc versus emicizumab in patients with haemophilia A without inhibitors in the UK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The cost\u2010effectiveness model was based on a matching\u2010adjusted indirect comparison and included male patients, aged \u226512\u2009years, with haemophilia A without inhibitors. The model was designed as a Markov process with a flexible lifelong time horizon, and cost\u2010effectiveness was presented as an incremental cost\u2010effectiveness ratio. Base\u2010case analysis and sensitivity analyses (including scenario analyses, one\u2010way deterministic sensitivity analysis [DSA] and probability sensitivity analysis [PSA]) were performed using the following treatment strategies: individualised prophylaxis with rFVIIIFc and prophylaxis with emicizumab administered once weekly (scenario analyses used regimens of once every 2\u2009weeks or once every 4\u2009weeks).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Base\u2010case analysis, DSA and PSA indicated that, compared with emicizumab administered once weekly, rFVIIIFc individualised prophylaxis was the dominant treatment strategy, with lower costs, a greater number of quality\u2010adjusted life years, and a lower number of bleeds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>rFVIIIFc has proven efficacy and is cost\u2010effective compared with emicizumab, providing clinicians with a viable treatment option to improve the health outcomes for adults and adolescents with haemophilia A in the UK.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13901","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T08:28:44Z","timestamp":1668760124000},"page":"262-270","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost\u2010effectiveness of recombinant factor <scp>VIII Fc<\/scp> versus emicizumab for prophylaxis in adults and adolescents with haemophilia <scp>A<\/scp> without inhibitors in the <scp>UK<\/scp>"],"prefix":"10.1111","volume":"110","author":[{"given":"Nana","family":"Kragh","sequence":"first","affiliation":[{"name":"Global Health Economics and Outcomes Research Swedish Orphan Biovitrum AB (Sobi\u2122)  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tytula","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Department Putnam PHMR  Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Pochopien","sequence":"additional","affiliation":[{"name":"Economic Modelling Assignity  Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Aball\u00e9a","sequence":"additional","affiliation":[{"name":"Public Health Department Aix\u2010Marseille University  Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[{"name":"Public Health Department Aix\u2010Marseille University  Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research Swedish Orphan Biovitrum AB (Sobi\u2122)  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jameel","family":"Nazir","sequence":"additional","affiliation":[{"name":"Patient Access and Community Engagement Swedish Orphan Biovitrum AB (Sobi\u2122)  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Bystrick\u00e1","sequence":"additional","affiliation":[{"name":"Medical Affairs and Clinical Science Haemophilia Swedish Orphan Biovitrum AB (Sobi\u2122)  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Fatoye","sequence":"additional","affiliation":[{"name":"Faculty of Health and Education Manchester Metropolitan University  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12,11]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Hemophilia WFH.Annual Global Survey. 2020. Available at:https:\/\/www1.wfh.org\/publications\/files\/pdf-2045.pdf(accessed 2 December 2022)."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-016-0785-2"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13027"},{"issue":"6","key":"e_1_2_11_5_1","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort L","year":"2019","journal-title":"Blood Transfus"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16704"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S80814"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13610"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13953"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.7.632"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1175-5"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-39"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0660-y"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1016228"},{"key":"e_1_2_11_21_1","unstructured":"Swedish Orphan Biovitrum AB (publ).Elocta Summary of Product Characteristics.2020. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/elocta\u2010epar\u2010product\u2010information_en.pdf(accessed 2 December 2022)."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13736"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S288283"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197703312961304"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000178830.39526.ff"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200220110-00005"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124421"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1405816"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_2_11_31_1","unstructured":"British National Formulary National Institute for Health and Care Excellence. Emicizumab Solution for Injection.2021. Available at:https:\/\/bnf.nice.org.uk\/medicinal-forms\/emicizumab.html(accessed 2 December 2022)."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13901","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T05:55:27Z","timestamp":1692510927000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,11]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/ejh.13901"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13901","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,11]]},"assertion":[{"value":"2022-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}